首页 > 最新文献

Journal of Thrombosis and Haemostasis最新文献

英文 中文
RUNX1 isoforms regulate RUNX1 and target genes differentially in platelets-megakaryocytes: association with clinical cardiovascular events. RUNX1 异构体对血小板-巨核细胞中的 RUNX1 和靶基因有不同的调控作用:与临床心血管事件的关系
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-23 DOI: 10.1016/j.jtha.2024.07.032
Liying Guan, Deepak Voora, Rachel Myers, Fabiola Del Carpio-Cano, A Koneti Rao

Background: Hematopoietic transcription factor RUNX1 is expressed from proximal P2 and distal P1 promoters to yield isoforms RUNX1 B and C, respectively. The roles of these isoforms in RUNX1 autoregulation and downstream gene regulation in megakaryocytes and platelets are unknown.

Objectives: To understand the regulation of RUNX1 and its target genes by RUNX1 isoforms.

Methods: We performed studies on RUNX1 isoforms in megakaryocytic human erythroleukemia (HEL) cells and HeLa cells (lack endogenous RUNX1), in platelets from 85 healthy volunteers administered aspirin or ticagrelor, and on the association of RUNX1 target genes with acute events in 587 patients with cardiovascular disease (CVD).

Results: In chromatin immunoprecipitation and luciferase promoter assays, RUNX1 isoforms B and C bound and regulated P1 and P2 promoters. In HeLa cells, RUNX1B decreased and RUNX1C increased P1 and P2 activities, respectively. In HEL cells, RUNX1B overexpression decreased RUNX1C and RUNX1A expression; RUNX1C increased RUNX1B and RUNX1A. RUNX1B and RUNX1C regulated target genes (MYL9, F13A1, PCTP, PDE5A, and others) differentially in HEL cells. In platelets, RUNX1B transcripts (by RNA sequencing) correlated negatively with RUNX1C and RUNX1A; RUNX1C correlated positively with RUNX1A. RUNX1B correlated positively with F13A1, PCTP, PDE5A, RAB1B, and others, and negatively with MYL9. In our previous studies, RUNX1C transcripts in whole blood were protective against acute events in CVD patients. We found that higher expression of RUNX1 targets F13A1 and RAB31 associated with acute events.

Conclusion: RUNX1 isoforms B and C autoregulate RUNX1 and regulate downstream genes in a differential manner, and this is associated with acute events in CVD.

背景:造血转录因子 RUNX1 由近端 P2 和远端 P1 启动子表达,分别产生异构体 RUNX1 B 和 C。这些异构体在巨核细胞和血小板中的 RUNX1 自调节和下游基因调节中的作用尚不清楚:目的:了解 RUNX1 及其靶基因受 RUNX1 同工酶调控的情况:我们对巨核细胞HEL细胞和HeLa细胞(缺乏内源性RUNX1)中的RUNX1同工酶、85名服用阿司匹林或替卡格雷的健康志愿者的血小板中的RUNX1同工酶以及587名心血管疾病(CVD)患者的RUNX1靶基因与急性事件的相关性进行了研究:结果:在染色质免疫沉淀和荧光素酶启动子试验中,RUNX1同工酶B和C与P1和P2启动子结合并对其进行调控。在 HeLa 细胞中,RUNX1B 分别降低了 P1 和 P2 的活性,而 RUNX1C 则提高了 P1 和 P2 的活性。在 HEL 细胞中,RUNX1B 过表达会降低 RUNX1C 和 RUNX1A 的表达;RUNX1C 会增加 RUNX1B 和 RUNX1A 的表达。在 HEL 细胞中,RUNX1B 和 RUNX1C 对靶基因(MYL9、F13A1、PCTP、PDE5A 等)的调控存在差异。在血小板中,RUNX1B 转录物(通过 RNAseq)与 RUNX1C 和 RUNX1A 呈负相关;RUNX1C 与 RUNX1A 呈正相关。RUNX1B 与 F13A1、PCTP、PDE5A、RAB1B 等呈正相关,与 MYL9 呈负相关。在我们之前的研究中,全血中的 RUNX1C 转录物对心血管疾病患者的急性事件具有保护作用。我们发现,RUNX1靶标F13A1和RAB31的高表达与急性事件有关:结论:RUNX1同工酶B和C以不同的方式自动调节RUNX1并调控下游基因,这与心血管疾病的急性事件有关。
{"title":"RUNX1 isoforms regulate RUNX1 and target genes differentially in platelets-megakaryocytes: association with clinical cardiovascular events.","authors":"Liying Guan, Deepak Voora, Rachel Myers, Fabiola Del Carpio-Cano, A Koneti Rao","doi":"10.1016/j.jtha.2024.07.032","DOIUrl":"10.1016/j.jtha.2024.07.032","url":null,"abstract":"<p><strong>Background: </strong>Hematopoietic transcription factor RUNX1 is expressed from proximal P2 and distal P1 promoters to yield isoforms RUNX1 B and C, respectively. The roles of these isoforms in RUNX1 autoregulation and downstream gene regulation in megakaryocytes and platelets are unknown.</p><p><strong>Objectives: </strong>To understand the regulation of RUNX1 and its target genes by RUNX1 isoforms.</p><p><strong>Methods: </strong>We performed studies on RUNX1 isoforms in megakaryocytic human erythroleukemia (HEL) cells and HeLa cells (lack endogenous RUNX1), in platelets from 85 healthy volunteers administered aspirin or ticagrelor, and on the association of RUNX1 target genes with acute events in 587 patients with cardiovascular disease (CVD).</p><p><strong>Results: </strong>In chromatin immunoprecipitation and luciferase promoter assays, RUNX1 isoforms B and C bound and regulated P1 and P2 promoters. In HeLa cells, RUNX1B decreased and RUNX1C increased P1 and P2 activities, respectively. In HEL cells, RUNX1B overexpression decreased RUNX1C and RUNX1A expression; RUNX1C increased RUNX1B and RUNX1A. RUNX1B and RUNX1C regulated target genes (MYL9, F13A1, PCTP, PDE5A, and others) differentially in HEL cells. In platelets, RUNX1B transcripts (by RNA sequencing) correlated negatively with RUNX1C and RUNX1A; RUNX1C correlated positively with RUNX1A. RUNX1B correlated positively with F13A1, PCTP, PDE5A, RAB1B, and others, and negatively with MYL9. In our previous studies, RUNX1C transcripts in whole blood were protective against acute events in CVD patients. We found that higher expression of RUNX1 targets F13A1 and RAB31 associated with acute events.</p><p><strong>Conclusion: </strong>RUNX1 isoforms B and C autoregulate RUNX1 and regulate downstream genes in a differential manner, and this is associated with acute events in CVD.</p>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gene therapy for people with hemophilia B: a proposed care delivery model in Italy 血友病 B 患者的基因治疗:意大利的一种拟议护理模式。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-22 DOI: 10.1016/j.jtha.2024.07.029
Giancarlo Castaman , Giovanni Di Minno , Paolo Simioni , Angelo Claudio Molinari , Sergio Siragusa , Erminia Baldacci , Vincenzo La Mura , Angelo Lupi , Enrico Ferri Grazzi , Flora Peyvandi

Background

Gene therapy is designed to provide people with hemophilia B with a steady and elevated factor (F)IX activity, thereby strengthening protection and relieving the burden of frequent replacement therapy infusions. The European Medicines Agency has approved gene therapy for the severe and moderately severe forms of hemophilia B that uses the FIX-Padua variant (etranacogene dezaparvovec).

Objectives

The aim was to provide a document dedicated to hemophilia B gene therapy and give a comprehensive overview of the topic.

Methods

An Italian group of experts in hemophilia carried out a narrative review of the literature and discussed during a virtual meeting several key aspects of the delivery of this treatment in Italy. The discussion covered the organizational model, the role of the multidisciplinary team, the laboratory surveillance, and the patient’s journey, from the follow-up to the identification of safety issues and outcome measures.

Results

This article highlights the need to follow the Hub and Spoke organizational model and sheds light on the role of each professional figure within the multidisciplinary teams to favor patient engagement, management, and retention. Moreover, this article stresses the need to perform laboratory tests for patient screening and follow-up and proposes a checklist to help patient identification. Finally, the needs of Italian hemophilia centers have been considered to ensure an efficient implementation of the care delivery model.

Conclusion

It is crucial to ensure that centers are appropriately organized, equipped, and trained to adequately select patients, deliver the gene therapy, and perform follow-up.
背景:基因疗法旨在为乙型血友病患者提供稳定、高活性的 IX 因子,从而加强保护并减轻频繁输注替代疗法的负担。欧洲药品管理局已经批准了一种针对重度和中度血友病 B 型的基因疗法,该疗法使用因子 IX 帕多瓦变体(etranacogene dezaparvovec)。本文旨在提供一份有关 B 型血友病基因疗法的专门文件,并对该主题进行全面概述:一个由血友病专家组成的意大利小组对文献进行了叙述性回顾,并在一次虚拟会议上讨论了在意大利提供这种治疗的几个关键方面。讨论内容包括组织模式、多学科团队的作用、实验室监测以及从随访到确定安全问题和结果衡量标准的患者治疗过程:结果:本文强调了遵循 "枢纽和辐条 "组织模式的必要性,并阐明了多学科团队中各专业人员的作用,以促进患者参与、管理和留住患者。此外,本文还强调了为患者筛查和随访进行实验室检测的必要性,并提出了一份有助于识别患者的核对表。最后,还考虑了意大利血友病中心的需求,以确保有效实施护理服务模式:至关重要的是,要确保各中心有适当的组织、设备和培训,以充分甄选患者、提供基因治疗和进行随访。
{"title":"Gene therapy for people with hemophilia B: a proposed care delivery model in Italy","authors":"Giancarlo Castaman ,&nbsp;Giovanni Di Minno ,&nbsp;Paolo Simioni ,&nbsp;Angelo Claudio Molinari ,&nbsp;Sergio Siragusa ,&nbsp;Erminia Baldacci ,&nbsp;Vincenzo La Mura ,&nbsp;Angelo Lupi ,&nbsp;Enrico Ferri Grazzi ,&nbsp;Flora Peyvandi","doi":"10.1016/j.jtha.2024.07.029","DOIUrl":"10.1016/j.jtha.2024.07.029","url":null,"abstract":"<div><h3>Background</h3><div>Gene therapy is designed to provide people with hemophilia B with a steady and elevated factor (F)IX activity, thereby strengthening protection and relieving the burden of frequent replacement therapy infusions. The European Medicines Agency has approved gene therapy for the severe and moderately severe forms of hemophilia B that uses the FIX-Padua variant (etranacogene dezaparvovec).</div></div><div><h3>Objectives</h3><div>The aim was to provide a document dedicated to hemophilia B gene therapy and give a comprehensive overview of the topic.</div></div><div><h3>Methods</h3><div>An Italian group of experts in hemophilia carried out a narrative review of the literature and discussed during a virtual meeting several key aspects of the delivery of this treatment in Italy. The discussion covered the organizational model, the role of the multidisciplinary team, the laboratory surveillance, and the patient’s journey, from the follow-up to the identification of safety issues and outcome measures.</div></div><div><h3>Results</h3><div>This article highlights the need to follow the Hub and Spoke organizational model and sheds light on the role of each professional figure within the multidisciplinary teams to favor patient engagement, management, and retention. Moreover, this article stresses the need to perform laboratory tests for patient screening and follow-up and proposes a checklist to help patient identification. Finally, the needs of Italian hemophilia centers have been considered to ensure an efficient implementation of the care delivery model.</div></div><div><h3>Conclusion</h3><div>It is crucial to ensure that centers are appropriately organized, equipped, and trained to adequately select patients, deliver the gene therapy, and perform follow-up.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelet HMGB1 steers intravascular immunity and thrombosis. 血小板 HMGB1 引导血管内免疫和血栓形成
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-22 DOI: 10.1016/j.jtha.2024.07.030
Norma Maugeri, Angelo A Manfredi

Platelets navigate the fine balance between homeostasis and injury. They regulate vascular homeostasis and drive repair after injury amidst leukocyte extravasation. Crucially, platelets initiate extracellular traps generation and promote immunothrombosis. In chronic human diseases, platelet action often extends beyond its normative role, sparking sustained reciprocal activation of leukocytes and mural cells, culminating in adverse vascular remodeling. Studies in the last decade have spotlighted a novel key player in platelet activation, the high mobility group box 1 (HMGB1) protein. Despite its initial characterization as a chromatin molecule, anucleated platelets express abundant HMGB1, which has emerged as a linchpin in thromboinflammatory risks and microvascular remodeling. We propose that a comprehensive assessment of platelet HMGB1, spanning quantification of content, membrane localization, and accumulation of HMGB1-expressing vesicles in biological fluids should be integral to dissecting and quantifying platelet activation. This review provides evidence supporting this claim and underscores the significance of platelet HMGB1 as a biomarker in conditions associated with heightened thrombotic risks and systemic microvascular involvement, spanning cardiovascular, autoimmune, and infectious diseases.

血小板在稳态和损伤之间保持着微妙的平衡。它们调节血管稳态,并在白细胞外渗的情况下推动损伤后的修复。最重要的是,血小板能启动细胞外陷阱的生成并促进免疫血栓形成。在人类慢性疾病中,血小板的作用往往超出其正常作用,引发白细胞和壁细胞的持续相互激活,最终导致不良的血管重塑。过去十年的研究发现了血小板活化过程中的一个新的关键角色--高迁移率基团框 1(HMGB1)蛋白。尽管高迁移率基团框 1 蛋白最初被定性为染色质分子,但无核血小板表达大量的 HMGB1,它已成为血栓炎症风险和微血管重塑的关键因素。我们建议对血小板 HMGB1 进行全面评估,包括对其含量、膜定位和生物液体中表达 HMGB1 的囊泡的积累进行量化,这对于剖析和量化血小板活化不可或缺。本综述提供了支持这一观点的证据,并强调了血小板 HMGB1 作为生物标记物在与血栓风险增加和全身微血管受累相关的疾病(包括心血管疾病、自身免疫性疾病和传染性疾病)中的重要性。
{"title":"Platelet HMGB1 steers intravascular immunity and thrombosis.","authors":"Norma Maugeri, Angelo A Manfredi","doi":"10.1016/j.jtha.2024.07.030","DOIUrl":"10.1016/j.jtha.2024.07.030","url":null,"abstract":"<p><p>Platelets navigate the fine balance between homeostasis and injury. They regulate vascular homeostasis and drive repair after injury amidst leukocyte extravasation. Crucially, platelets initiate extracellular traps generation and promote immunothrombosis. In chronic human diseases, platelet action often extends beyond its normative role, sparking sustained reciprocal activation of leukocytes and mural cells, culminating in adverse vascular remodeling. Studies in the last decade have spotlighted a novel key player in platelet activation, the high mobility group box 1 (HMGB1) protein. Despite its initial characterization as a chromatin molecule, anucleated platelets express abundant HMGB1, which has emerged as a linchpin in thromboinflammatory risks and microvascular remodeling. We propose that a comprehensive assessment of platelet HMGB1, spanning quantification of content, membrane localization, and accumulation of HMGB1-expressing vesicles in biological fluids should be integral to dissecting and quantifying platelet activation. This review provides evidence supporting this claim and underscores the significance of platelet HMGB1 as a biomarker in conditions associated with heightened thrombotic risks and systemic microvascular involvement, spanning cardiovascular, autoimmune, and infectious diseases.</p>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Production of physiological amounts of hemostatic proteins by human donor livers during ex situ long-term normothermic machine perfusion for up to 7 days 在长达七天的原位长期常温机器灌注过程中,人体捐献肝脏产生生理数量的止血蛋白。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-22 DOI: 10.1016/j.jtha.2024.08.004
Bianca Lascaris , Silke B. Bodewes , Jelle Adelmeijer , Maarten W.N. Nijsten , Robert J. Porte , Vincent E. de Meijer , Ton Lisman

Background

Normothermic machine perfusion (NMP) is used for preservation and assessment of human donor livers prior to transplantation. During NMP, the liver is metabolically active, which allows detailed studies on the physiology of human livers.

Objectives

To study the production of hemostatic proteins in human donor livers during NMP for up to 7 days.

Methods

In this observational study, 9 livers underwent NMP for up to 7 days with a heparinized perfusate based on red blood cells and colloids using a modified Liver Assist device (XVIVO). Perfusate samples were collected before NMP and daily thereafter for measurement of antigen and activity levels of a comprehensive panel of hemostatic proteins after heparin neutralization.

Results

Within 1 day, perfusate samples displayed the potential for coagulation activation as evidenced by international normalized ratio and activated partial thromboplastin assays. This was accompanied by detection of substantial quantities of functionally active coagulation proteins and inhibitors, although the specific activity of many proteins was decreased, compared with that in normal plasma. Perfusate levels of hemostatic proteins increased in the first days, reaching a stable level after 3 to 4 days of perfusion.

Conclusion

During long-term NMP of human livers, functionally active hemostatic proteins are released into the perfusate in substantial quantities, but some proteins appear to have decreased functional properties compared with proteins in normal human plasma. We propose that NMP may be used as a platform to test efficacy of drugs that stimulate or inhibit the production of coagulation factors or to test liver-mediated clearance of prohemostatic protein therapeutics.
背景:常温机器灌注(NMP)用于保存和评估移植前的人体捐献肝脏。在 NMP 期间,肝脏新陈代谢活跃,可以对人体肝脏的生理机能进行详细研究:研究人体供体肝脏在长达 7 天的 NMP 期间止血蛋白的生成情况:在这项观察性研究中,九个肝脏接受了长达 7 天的 NMP,并使用改良的肝脏辅助装置获得了以红细胞和胶体为基础的肝素化灌注液。在进行 NMP 之前收集灌注液样本,之后每天收集样本,以便在肝素中和后测量止血蛋白综合面板的抗原和活性水平:结果:在一天内,灌注液样本显示出凝血活化的可能性,国际归一化比率和活化部分凝血活酶检测证明了这一点。与正常血浆相比,虽然许多蛋白的特异性活性降低了,但同时还检测到了大量具有功能活性的凝血蛋白和抑制剂。灌流液中的止血蛋白水平在最初几天有所增加,在灌流 3-4 天后达到稳定水平:结论:在对人类肝脏进行长期 NMP 灌注期间,大量具有功能活性的止血蛋白被释放到灌流液中,但与正常人血浆中的蛋白相比,某些蛋白的功能特性似乎有所下降。我们建议将 NMP 作为一个平台,用于测试刺激或抑制凝血因子产生的药物的疗效,或测试肝脏介导的止血蛋白治疗药物的清除率。
{"title":"Production of physiological amounts of hemostatic proteins by human donor livers during ex situ long-term normothermic machine perfusion for up to 7 days","authors":"Bianca Lascaris ,&nbsp;Silke B. Bodewes ,&nbsp;Jelle Adelmeijer ,&nbsp;Maarten W.N. Nijsten ,&nbsp;Robert J. Porte ,&nbsp;Vincent E. de Meijer ,&nbsp;Ton Lisman","doi":"10.1016/j.jtha.2024.08.004","DOIUrl":"10.1016/j.jtha.2024.08.004","url":null,"abstract":"<div><h3>Background</h3><div>Normothermic machine perfusion (NMP) is used for preservation and assessment of human donor livers prior to transplantation. During NMP, the liver is metabolically active, which allows detailed studies on the physiology of human livers.</div></div><div><h3>Objectives</h3><div>To study the production of hemostatic proteins in human donor livers during NMP for up to 7 days.</div></div><div><h3>Methods</h3><div>In this observational study, 9 livers underwent NMP for up to 7 days with a heparinized perfusate based on red blood cells and colloids using a modified Liver Assist device (XVIVO). Perfusate samples were collected before NMP and daily thereafter for measurement of antigen and activity levels of a comprehensive panel of hemostatic proteins after heparin neutralization.</div></div><div><h3>Results</h3><div>Within 1 day, perfusate samples displayed the potential for coagulation activation as evidenced by international normalized ratio and activated partial thromboplastin assays. This was accompanied by detection of substantial quantities of functionally active coagulation proteins and inhibitors, although the specific activity of many proteins was decreased, compared with that in normal plasma. Perfusate levels of hemostatic proteins increased in the first days, reaching a stable level after 3 to 4 days of perfusion.</div></div><div><h3>Conclusion</h3><div>During long-term NMP of human livers, functionally active hemostatic proteins are released into the perfusate in substantial quantities, but some proteins appear to have decreased functional properties compared with proteins in normal human plasma. We propose that NMP may be used as a platform to test efficacy of drugs that stimulate or inhibit the production of coagulation factors or to test liver-mediated clearance of prohemostatic protein therapeutics.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early thrombus formation is required for eccentric and heterogeneous neointimal hyperplasia under disturbed flow. 在血流紊乱的情况下,偏心和异源性新内膜增生需要早期血栓形成。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-21 DOI: 10.1016/j.jtha.2024.07.028
Hualong Bai, Zhuo Li, Weichang Zhang, Carly Thaxton, Yuichi Ohashi, Luis Gonzalez, Masaki Kano, Bogdan Yatsula, John Hwa, Alan Dardik

Background: Anticoagulation and antiplatelet therapy effectively inhibit neointimal hyperplasia (NIH) in both arterial and venous systems but not in arteriovenous fistulae (AVF). The main site of AVF failure is the juxta-anastomotic area that is characterized by disturbed flow compared with laminar flow in the arterial inflow and the venous outflow.

Objectives: We hypothesized that early thrombus formation is required for eccentric and heterogeneous NIH in the presence of disturbed flow.

Methods: Needle puncture and sutured AVF were created in C57BL/6 mice, in PF4-Cre × mT/mG reporter mice, and in Wistar rats. Human AVF samples were second-stage basilic vein transpositions. The tissues were examined by histology, immunofluorescence, immunohistochemistry, and en face staining.

Results: In the presence of disturbed flow, both mouse and human AVF showed eccentric and heterogeneous NIH. Maladapted vein wall was characterized by eccentric and heterogeneous neointima that was composed of a different abundance of thrombus and smooth muscle cells. PF4-cre × mT/mG reporter mice AVF showed that green fluorescent protein-labeled platelets deposit on the wall directly facing the fistula exit with endothelial cell loss and continue to accumulate in the presence of disturbed flow. Neither disturbed flow with limited endothelial cell loss nor nondisturbed flow induced heterogeneous neointima in different animal models.

Conclusion: Early thrombus contributes to late heterogeneous NIH in the presence of disturbed flow. Disturbed flow, large area of endothelial cell loss, and thrombus formation are critical to form eccentric and heterogeneous NIH. Categorization of adapted or maladapted walls may be helpful for therapy targeting heterogeneous NIH.

背景:抗凝和抗血小板疗法能有效抑制动脉和静脉系统的新内膜增生(NIH),但不能抑制动静脉瘘(AVF)。动静脉瘘失败的主要部位是吻合口附近区域,与动脉流入和静脉流出的层流相比,该区域的特点是血流紊乱。我们假设,在血流紊乱的情况下,偏心和异源性 NIH 需要早期血栓形成:方法:在 C57BL/6 小鼠、PF4-cre × mT/mG 报告小鼠和 Wistar 大鼠身上建立针刺和缝合的动静脉瘘。转位收获人类动静脉瘘样本。通过组织学、免疫荧光、免疫组织化学和表面染色对组织进行检查:结果:在血流紊乱的情况下,小鼠和人类的动静脉瘘都表现出偏心和异质的 NIH。适应不良的静脉壁表现为偏心和异质的新内膜,由不同数量的血栓和平滑肌细胞(SMC)组成。PF4-cre × mT/mG 报告小鼠 AVF 显示,GFP 标记的血小板沉积在直接面向瘘管出口的静脉壁上,内皮细胞脱落,并在血流紊乱的情况下继续聚集。在不同的动物模型中,内皮细胞损失有限的干扰血流和非干扰血流都不会诱发异源性新生内膜:结论:在血流紊乱的情况下,早期血栓会导致晚期异源性新生内膜。干扰血流、大面积内皮细胞缺失和血栓形成是形成偏心和异源性 NIH 的关键。对适应或不适应的血管壁进行分类可能有助于针对异源性 NIH 的治疗。
{"title":"Early thrombus formation is required for eccentric and heterogeneous neointimal hyperplasia under disturbed flow.","authors":"Hualong Bai, Zhuo Li, Weichang Zhang, Carly Thaxton, Yuichi Ohashi, Luis Gonzalez, Masaki Kano, Bogdan Yatsula, John Hwa, Alan Dardik","doi":"10.1016/j.jtha.2024.07.028","DOIUrl":"10.1016/j.jtha.2024.07.028","url":null,"abstract":"<p><strong>Background: </strong>Anticoagulation and antiplatelet therapy effectively inhibit neointimal hyperplasia (NIH) in both arterial and venous systems but not in arteriovenous fistulae (AVF). The main site of AVF failure is the juxta-anastomotic area that is characterized by disturbed flow compared with laminar flow in the arterial inflow and the venous outflow.</p><p><strong>Objectives: </strong>We hypothesized that early thrombus formation is required for eccentric and heterogeneous NIH in the presence of disturbed flow.</p><p><strong>Methods: </strong>Needle puncture and sutured AVF were created in C57BL/6 mice, in PF4-Cre × mT/mG reporter mice, and in Wistar rats. Human AVF samples were second-stage basilic vein transpositions. The tissues were examined by histology, immunofluorescence, immunohistochemistry, and en face staining.</p><p><strong>Results: </strong>In the presence of disturbed flow, both mouse and human AVF showed eccentric and heterogeneous NIH. Maladapted vein wall was characterized by eccentric and heterogeneous neointima that was composed of a different abundance of thrombus and smooth muscle cells. PF4-cre × mT/mG reporter mice AVF showed that green fluorescent protein-labeled platelets deposit on the wall directly facing the fistula exit with endothelial cell loss and continue to accumulate in the presence of disturbed flow. Neither disturbed flow with limited endothelial cell loss nor nondisturbed flow induced heterogeneous neointima in different animal models.</p><p><strong>Conclusion: </strong>Early thrombus contributes to late heterogeneous NIH in the presence of disturbed flow. Disturbed flow, large area of endothelial cell loss, and thrombus formation are critical to form eccentric and heterogeneous NIH. Categorization of adapted or maladapted walls may be helpful for therapy targeting heterogeneous NIH.</p>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CpG oligonucleotides induce acute murine thrombocytopenia dependent on toll-like receptor 9 and spleen tyrosine kinase pathways CpG寡核苷酸会诱发依赖于收费样受体9和脾脏酪氨酸激酶途径的急性小鼠血小板减少症。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-21 DOI: 10.1016/j.jtha.2024.08.003
Karl Johansson , Amal Maouia , Johan Rebetz , Geneviève Marcoux , Oonagh Shannon , Joseph E. Italiano Jr. , Padma Narayanan , Scott Henry , Lijiang Shen , John W. Semple

Background

CpG oligonucleotides (ODNs) are synthetic single-stranded DNA sequences that act as immunostimulants. They have been increasingly used to treat several cancers; however, thrombocytopenia is a potential recognized side effect of some sequences.

Objectives

We tested the ability of 2 CpG ODNs (ODN 2395 and ISIS 120704) to induce thrombocytopenia when administered to BALB/c mice and determined mechanisms associated with thrombocytopenia.

Methods

BALB/c mice were prebled and then injected with titrated doses of CpG ODNs, and platelet counts were determined. The mice were treated with intravenous immunoglobulin (IVIg) or various inhibitors and antagonists of toll-like receptor 9 (TLR9) and spleen tyrosine kinase (Syk) to determine their effects on thrombocytopenia.

Results

Compared with saline-treated mice or mice treated with 2′-O-methoxyethyl–modified antisense ODN, both ODN 2395 and ISIS 120704 induced acute dose-dependent thrombocytopenia within 3 and 24 hours, respectively. The thrombocytopenia was associated with significant increases in plasma monocyte chemoattractant protein 1. IVIg administration significantly rescued the CpG ODN–induced thrombocytopenia, as did treatment with either a Syk inhibitor or TLR9 antagonists. In vitro, CpG ODN could activate human platelets and this correlated significantly with enhanced IVIg- and Syk-dependent phagocytosis by THP-1 monocytes.

Conclusion

These results suggest that CpG ODNs induce acute inflammatory-associated (IVIg-sensitive) thrombocytopenia that can be alleviated by Syk- or TLR9-blockade, and an IVIg- and Syk-dependent platelet clearance pathway appears primarily responsible for the thrombocytopenia.
背景CpG ODN 是合成的单链 DNA 序列,可作为免疫刺激剂。它们越来越多地被用于治疗多种癌症,然而,血小板减少症是某些序列公认的潜在副作用:我们测试了两种 CpG ODN(ODN 2395 和 ISIS 120704)给 BALB/c 小鼠注射后诱导血小板减少的能力,并确定了与血小板减少相关的机制:预先饲养 BALB/c 小鼠,然后注射滴定剂量的 CpG ODN,测定血小板计数。对小鼠进行 IVIg 处理或使用各种收费样受体 9(TLR9)和脾脏酪氨酸激酶(Syk)的抑制剂和拮抗剂,以确定它们对血小板减少的影响:与生理盐水处理的小鼠或2'-O-甲氧基乙基(MOE)修饰的反义(ASO)ODN处理的小鼠相比,ODN 2395和ISIS 120704分别在3小时和24小时内诱导急性剂量依赖性血小板减少。血小板减少与血浆单核细胞趋化蛋白 1(MCP1)的显著增加有关。静脉注射免疫球蛋白(IVIg)能明显缓解 CpG ODN 诱导的血小板减少症,Syk-抑制剂或 TLR9 拮抗剂也能缓解该症状。在体外,CpG ODN 可激活人血小板,这与 THP-1 单核细胞增强的 IVIg 和 Syk 依赖性吞噬作用密切相关。这些结果表明,CpG ODN 会诱发急性炎症相关性(IVIg 敏感性)血小板减少症,Syk 或 TLR9 受体阻断剂可减轻这种症状,而 IVIg 和 Syk 依赖性血小板清除途径似乎是造成血小板减少症的主要原因。这些结果是否适用于人类仍有待阐明。
{"title":"CpG oligonucleotides induce acute murine thrombocytopenia dependent on toll-like receptor 9 and spleen tyrosine kinase pathways","authors":"Karl Johansson ,&nbsp;Amal Maouia ,&nbsp;Johan Rebetz ,&nbsp;Geneviève Marcoux ,&nbsp;Oonagh Shannon ,&nbsp;Joseph E. Italiano Jr. ,&nbsp;Padma Narayanan ,&nbsp;Scott Henry ,&nbsp;Lijiang Shen ,&nbsp;John W. Semple","doi":"10.1016/j.jtha.2024.08.003","DOIUrl":"10.1016/j.jtha.2024.08.003","url":null,"abstract":"<div><h3>Background</h3><div>CpG oligonucleotides (ODNs) are synthetic single-stranded DNA sequences that act as immunostimulants. They have been increasingly used to treat several cancers; however, thrombocytopenia is a potential recognized side effect of some sequences.</div></div><div><h3>Objectives</h3><div>We tested the ability of 2 CpG ODNs (ODN 2395 and ISIS 120704) to induce thrombocytopenia when administered to BALB/c mice and determined mechanisms associated with thrombocytopenia.</div></div><div><h3>Methods</h3><div>BALB/c mice were prebled and then injected with titrated doses of CpG ODNs, and platelet counts were determined. The mice were treated with intravenous immunoglobulin (IVIg) or various inhibitors and antagonists of toll-like receptor 9 (TLR9) and spleen tyrosine kinase (Syk) to determine their effects on thrombocytopenia.</div></div><div><h3>Results</h3><div>Compared with saline-treated mice or mice treated with 2′-O-methoxyethyl–modified antisense ODN, both ODN 2395 and ISIS 120704 induced acute dose-dependent thrombocytopenia within 3 and 24 hours, respectively. The thrombocytopenia was associated with significant increases in plasma monocyte chemoattractant protein 1. IVIg administration significantly rescued the CpG ODN–induced thrombocytopenia, as did treatment with either a Syk inhibitor or TLR9 antagonists. <em>In vitro</em>, CpG ODN could activate human platelets and this correlated significantly with enhanced IVIg- and Syk-dependent phagocytosis by THP-1 monocytes.</div></div><div><h3>Conclusion</h3><div>These results suggest that CpG ODNs induce acute inflammatory-associated (IVIg-sensitive) thrombocytopenia that can be alleviated by Syk- or TLR9-blockade, and an IVIg- and Syk-dependent platelet clearance pathway appears primarily responsible for the thrombocytopenia.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19”: comment from Flumignan et al. "2023年ISTH对2022年ISTH COVID-19抗血栓治疗指南的更新":Flumignan等人的评论。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-20 DOI: 10.1016/j.jtha.2024.05.029
Ronald Luiz Gomes Flumignan , Luis Carlos Uta Nakano , Jorge Eduardo de Amorim , Álvaro Nagib Atallah
{"title":"“2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19”: comment from Flumignan et al.","authors":"Ronald Luiz Gomes Flumignan ,&nbsp;Luis Carlos Uta Nakano ,&nbsp;Jorge Eduardo de Amorim ,&nbsp;Álvaro Nagib Atallah","doi":"10.1016/j.jtha.2024.05.029","DOIUrl":"10.1016/j.jtha.2024.05.029","url":null,"abstract":"","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al. 使用2018-2022年美国食品和药物管理局不良事件报告系统数据比较接受第八因子产品和埃米珠单抗治疗的患者血栓性不良事件:来自Berkowitz等人的评论。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-20 DOI: 10.1016/j.jtha.2024.04.027
Callie Berkowitz , Samuel Wilson , Nigel S. Key , Patrick Ellsworth
{"title":"Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.","authors":"Callie Berkowitz ,&nbsp;Samuel Wilson ,&nbsp;Nigel S. Key ,&nbsp;Patrick Ellsworth","doi":"10.1016/j.jtha.2024.04.027","DOIUrl":"10.1016/j.jtha.2024.04.027","url":null,"abstract":"","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The enigma of factor XII surface binding 因子 XII 表面结合之谜
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-20 DOI: 10.1016/j.jtha.2024.07.004
Sadiq Silbak , Alvin H. Schmaier
{"title":"The enigma of factor XII surface binding","authors":"Sadiq Silbak ,&nbsp;Alvin H. Schmaier","doi":"10.1016/j.jtha.2024.07.004","DOIUrl":"10.1016/j.jtha.2024.07.004","url":null,"abstract":"","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ISTH News and Updates: Join the ISTH Today ISTH 新闻和更新:立即加入 ISTH
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-20 DOI: 10.1016/S1538-7836(24)00475-6
{"title":"ISTH News and Updates: Join the ISTH Today","authors":"","doi":"10.1016/S1538-7836(24)00475-6","DOIUrl":"10.1016/S1538-7836(24)00475-6","url":null,"abstract":"","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1538783624004756/pdfft?md5=ce08ba881e286c5470efacc03d0c9316&pid=1-s2.0-S1538783624004756-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Thrombosis and Haemostasis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1